乙肝病毒相关疾病住院病人十二个城市在中国的年度经济负

StephenW

Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China

    S. Zhang1,*, Q. Ma1,2, S. Liang1,3, H. Xiao1,4, G. Zhuang5,†, Y. Zou2, H. Tan4, J. Liu6, Y. Zhang7, L. Zhang8, X. Feng9, L. Xue10, D. Hu3, F. Cui11 andX. Liang11,†

Article first published online: 10 DEC 2015

DOI: 10.1111/jvh.12482

© 2015 John Wiley & Sons Ltd

Issue
Cover image for Vol. 23 Issue 1
Journal of Viral Hepatitis

Early View (Online Version of Record published before inclusion in an issue)
    1    Division of Communicable Diseases, Shenzhen CDC, Shenzhen, China
    2    Department of Social Medicine, Guangdong Pharmaceutical College, Guangzhou, China
    3    Department of Epidemiology and Biostatistics, Zhengzhou University School of Public Health, Zhengzhou, China
    4    Department of Epidemiology and Biostatistics, Central South University School of Public Health, Changsha, China
    5    Department of Epidemiology and Biostatistics, Xi'an Jiaotong University School of Public Health, Xi'an, China
    6    Department of Gastrointestinal Disease, First Hospital of Shanxi Medical University, Taiyuan, China
    7    Department of Epidemiology and Biostatistics, Ningxia Medical University School of Public Health, Yinchuan, China
    8    Institute of Immunization, Shandong CDC, Jinan, China
    9    Department of Preventive Medicine, Changzhi Medical College, Changzhi, China
    10    University at Buffalo School of Medicine, Buffalo, NY, USA
    11    National Immunization Program, China CDC, Beijing, China

    †    These authors contributed equally to the study.

*Correspondence: Shunxiang Zhang, Division of Communicable Diseases, Shenzhen CDC, NO. 8 Longyuan Road, Longzhu Avenue, Nanshan District, Shenzhen, 518055, China. E-mail: Zhang SX, [email protected]


Keywords:

    cost analysis;direct cost;hepatitis b;indirect cost;intangible cost

Summary

A nationwide survey of hepatitis B virus (HBV)-associated economic burden has not previously been performed in China. The purpose of this study was to examine the direct, indirect, and intangible costs of HBV-related diseases within the span of one year. A random sample was taken from specialty and general hospitals across 12 cities in six provinces of China. Intangible costs were estimated based on willingness to pay or open-ended answers provided by patients. The results showed that 27 hospitals were enrolled, with a sample population of 4726 patients (77.7% response rate). The average annual costs were $4454.0 (direct), $924.3 (indirect), and $6611.10 (intangible), corresponding to 37.3%, 7.7%, and 55.1% of the total costs, respectively. The direct medical fees were substantially greater than the non-medical fees. Annual indirect costs were divided into outpatient ($112.9) and inpatient ($811.40) loss of income. The intangible costs of chronic HBV were notably higher than either the direct or indirect costs, consistent with the social stigma in China. The comparison amongst individual cities for the average ratio of direct to indirect costs revealed that the sizes of ratios were negatively correlated with the socioeconomic status of the regions. This study suggested that as a whole in China, the HBV-related diseases caused a heavy financial burden which was positively associated with disease severity. Although the intangible costs coincided with a high prevalence of discrimination against CHB patients in Chinese society, our study may serve as future reference for detailed exploration.

StephenW

乙肝病毒相关疾病住院病人十二个城市在中国的年度经济负担

    S. Zhang1，*，问：Ma1,2，S. Liang1,3，H Xiao1,4，G Zhuang5，†，Y. Zou2，H Tan4，J. Liu6，Y. Zhang7，L. Zhang8，十Feng9，L. Xue10，D HU3，F Cui11及X。 Liang11，†

文章首次在网上公布：2015年12月10日

DOI：10.1111 / jvh.12482

©2015年约翰·威利父子有限公司

问题
封面图片卷。 23第1期
杂志病毒性肝炎

早期的浏览（包含之前录制的网上版本发表在一期）
    传染病1处，深圳市疾病预防控制中心，深圳，中国
    社会医学，广东药学院，广州，中国的2部
    流行病与卫生统计学，郑州大学公共卫生学院，郑州，中国的3系
    流行病与卫生统计学，中南大学公共卫生学院，长沙，中国的4部
    流行病与卫生统计学，西安交通大学公共卫生学院，西安，中国的5系
    胃肠道疾病，山西医科大学第一医院，太原，中国的6系
    流行病与卫生统计学，宁夏医科大学公共卫生学院，银川，中国的7系
    免疫接种，疾病预防控制中心山东济南，中国8个研究所
    预防医学，长治医学院，长治，中国的9部
    10大学医学院，布法罗，纽约，美国布法罗学院
    11国家免疫计划，中国疾病预防控制中心，北京，中国

    †这些作者同等贡献的研究。

*通讯：顺祥张，传染病科，深圳市疾病预防控制中心，NO。 8龙源路，龙珠大道，南山区，深圳，518055，中国。电子邮件：张SX，[email protected]


关键词：

    成本分析;直接成本;乙型肝炎;间接成本，无形成本

概要

以前没有在中国被执行的乙肝病毒（HBV）相关的经济负担的一项全国性调查。这项研究的目的是检查乙肝相关疾病一年跨度中的直接，间接和无形成本。随机抽样是从专业和综合性医院在12个城市在中国的六个省份。基于支付意愿或患者提供开放式的答案估计无形成本。结果表明，27家医院入选，与4726例（77.7％的回应率），样本人口。年平均费用为$四千四百五十四点零（直接），$ 9243（间接）和$六千六百十一点一○（无形），分别对应37.3％，7.7％，而总成本的55.1％。直接医疗费用比非医疗费大得多。年度间接成本分为门诊（$ 112.9）和住院（$八百十一点四零）收入损失。慢性乙肝的无形成本均显着高于无论是直接或间接的成本，随着社会的耻辱在中国一贯的高。直接间接费用的平均比例各个城市之间的比较显示比例的大小呈负与地区的社会经济状况密切相关。这项研究表明，作为一个整体在中国，乙肝相关疾病引起这是积极与疾病严重程度相关的沉重的经济负担。虽然无形成本恰逢对慢性乙型肝炎患者在中国社会歧视的高患病率，我们的研究可以作为详细勘探将来参考。